Dynavax/$DVAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dynavax
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Ticker
$DVAX
Sector
Primary listing
Employees
405
Headquarters
Website
Dynavax Metrics
BasicAdvanced
$1.1B
-
-$0.42
1.09
-
Price and volume
Market cap
$1.1B
Beta
1.09
52-week high
$14.63
52-week low
$9.22
Average daily volume
1.8M
Financial strength
Current ratio
6.646
Quick ratio
5.191
Long term debt to equity
61.935
Total debt to equity
58.597
Interest coverage (TTM)
1.20%
Profitability
EBITDA (TTM)
12.896
Gross margin (TTM)
64.15%
Net profit margin (TTM)
-16.67%
Operating margin (TTM)
2.57%
Effective tax rate (TTM)
-7.16%
Revenue per employee (TTM)
$780,000
Management effectiveness
Return on assets (TTM)
0.52%
Return on equity (TTM)
-9.28%
Valuation
Price to revenue (TTM)
3.743
Price to book
2.23
Price to tangible book (TTM)
2.24
Price to free cash flow (TTM)
17.92
Free cash flow yield (TTM)
5.58%
Free cash flow per share (TTM)
0.525
Growth
Revenue change (TTM)
26.66%
Earnings per share change (TTM)
-429.72%
3-year revenue growth (CAGR)
-22.28%
10-year revenue growth (CAGR)
47.11%
3-year earnings per share growth (CAGR)
-35.28%
10-year earnings per share growth (CAGR)
-19.48%
What the Analysts think about Dynavax
Analyst ratings (Buy, Hold, Sell) for Dynavax stock.
Bulls say / Bears say
HEPLISAV-B posted net product revenue of $91.9 million in Q2 2025, a 31% increase year-over-year—the highest quarterly sales on record. (Reuters)
Dynavax increased its full-year 2025 HEPLISAV-B revenue guidance to $315 million–$325 million, up from $305 million–$325 million, showing greater confidence in continued market growth. (Reuters)
HEPLISAV-B’s U.S. adult hepatitis B vaccine market share reached about 45%, up from 42% a year earlier, strengthening its competitive position. (Reuters)
Dynavax’s success depends on the upcoming Phase 1/2 shingles vaccine data, due in August 2025. This creates a binary risk for the stock—any disappointing results could lead to significant share pressure. (Reuters)
Total operating expenses increased to $81.01 million in Q2 2025, reflecting higher R&D and SG&A spending. This could squeeze margins if revenue growth slows. (Reuters)
The forward P/E ratio climbed to 87, compared to 27 three months ago, raising valuation risk and the potential for share price swings if growth expectations are not met. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Dynavax Financial Performance
Revenues and expenses
Dynavax Earnings Performance
Company profitability
Dynavax News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dynavax stock?
Dynavax (DVAX) has a market cap of $1.1B as of September 15, 2025.
What is the P/E ratio for Dynavax stock?
The price to earnings (P/E) ratio for Dynavax (DVAX) stock is 0 as of September 15, 2025.
Does Dynavax stock pay dividends?
No, Dynavax (DVAX) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Dynavax dividend payment date?
Dynavax (DVAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Dynavax?
Dynavax (DVAX) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.